24 related articles for article (PubMed ID: 38373017)
1. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
[TBL] [Abstract][Full Text] [Related]
2. An additional CD28 costimulatory signal enhances proliferation and cytotoxicity of murine T cell-derived CIK cell.
Timalsena S; Pluangnooch P; Wongkajornsilp A; Soontrapa K
Asian Pac J Allergy Immunol; 2017 Jun; 35(2):67-74. PubMed ID: 27543727
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.
Tao L; Huang G; Shi S; Chen L
Med Oncol; 2014 Jan; 31(1):777. PubMed ID: 24271420
[TBL] [Abstract][Full Text] [Related]
4. A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines.
Li Y; Sharma A; Wu X; Weiher H; Skowasch D; Essler M; Schmidt-Wolf IGH
Front Oncol; 2022; 12():713476. PubMed ID: 35646685
[TBL] [Abstract][Full Text] [Related]
5. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
6. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
7. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis.
Ma Y; Zhang Z; Tang L; Xu YC; Xie ZM; Gu XF; Wang HX
Cytotherapy; 2012 Apr; 14(4):483-93. PubMed ID: 22277010
[TBL] [Abstract][Full Text] [Related]
8. How can Cytokine-induced killer cells overcome CAR-T cell limits.
Cappuzzello E; Vigolo E; D'Accardio G; Astori G; Rosato A; Sommaggio R
Front Immunol; 2023; 14():1229540. PubMed ID: 37675107
[TBL] [Abstract][Full Text] [Related]
9. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
Linn YC; Hui KM
Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
[TBL] [Abstract][Full Text] [Related]
10. Can the dual-functional capability of CIK cells be used to improve antitumor effects?
Wang X; Yu W; Li H; Yu J; Zhang X; Ren X; Cao S
Cell Immunol; 2014 Jan; 287(1):18-22. PubMed ID: 24355711
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials.
Lv Y; Zhao H; Liu S; Meng Y; Yu W; Liu T; Sun Q; Shen M; Ren X; Liu L
J Leukoc Biol; 2024 Feb; ():. PubMed ID: 38373017
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]